Study About Hepatic Toxins Kinetic and Evaluation of Organ Damage in Acute on Chronic Liver Failure (ACLF) Patients
Recruiting now
Conditions studied: Acute on Chronic Liver Failure (ACLF)
In brief
Spontaneous Observational Prospective Multicenter study of all patients admitted to Intensive Care with a diagnosis of Acute on Chronic Liver Failure (ACLF) of grade ≥ 2 for which the use of the system will be authorized extracorporeal purification with DM CYTOSORB. The hypothesis underlying the study is to evaluate whether the modulation of bilirubin and other toxic molecules and mediators, obtainable through the use of systems extracorporeal purification (specifically DM CYTOSORB), may have an impacton the degree of organ failure in patients with ACLF. The study proposes the compilation of a structured and shared data collection with other Italian Intensive Care Centers which include patients suffering from ACLF (multicenter study) of clinical and laboratory parameters, which are part of normal clinical practice.
Key facts
- Study ID
- NCT06837766
- Run by
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- People needed
- 40
- Starts
- 2021-09-29
- Expected to finish
- 2025-12-31
- Last updated by the study team
- 2025-02-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- diagnosis of acute hepatic decompensation on chronic liver disease with grade ACLF ≥ 2 (diagnosable in the presence of at least two defined organ failures according to the CLIF-C-OF score);
- hemoabsorbent treatment with Cytosorb;
- patients aged ≥ 18 years at the time of diagnosis;
- Informed Consent.
You may not qualify if…
- patients aged < 18 years;
- fulminant liver failure;
- chronic end-stage liver failure with chronic encephalopathy and/or chronic refractory ascites;
- acute on chronic hepatic decompensation with grade 0 or 1 ACLF;
- clinical signs or history of congestive heart failure (NYHA class 3-4 before the acute phase of the disease or documented EF < 35% or PCWP > 18 mmHg) or acute coronary syndrome
- state of immunosuppression (rheumatological and immunological diseases, HIV, immunosuppressive therapy);
- previous organ transplant.
Where it is running
- Azienda Ospedaliero-Universitaria Ospedale Riuniti Umberto I - GM Lancisi - G Salesi, Ancona — Ancona, Ancona, Italy (enrolling)
- IRCCS Azienda Ospedaliero Universitaria di Bologna — Bologna, Bologna, Italy (enrolling)
- Anestesia e Rianimazione 2, Ospedale Niguarda Ca' Granda, Milano — Milan, Milano, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.